Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-01-19 / Genes Immun 2022 02;23(1):1-11A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-12-03 / Clin Cancer Res 2021 Dec;Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-02 / Front Immunol 2021;12:770390The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-01 / Clin Neuropharmacol 2021 Nov-Dec 01;44(6):216-221Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-10-05 / Front Immunol 2021;12:721830Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-05-10 / Front Oncol 2021;11:672508Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review
/in Glioblastoma, Hyperthermia, International Publications /von 2021-03-13 / J Neurooncol 2021 May;152(3):419-428DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2021-02-25 / Neuro Oncol 2021 02;23(2):240-250
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de